

1 Incretin hypersecretion in gestational 2 diabetes mellitus

3 4 Short running title: Incretins in GDM

5
6 Louise Fritsche^{1,2}, Martin Heni^{1,2,3,4}, Sabine S. Eckstein^{1,2}, Julia Hummel^{1,2}, Anette
7 Schürmann^{2,5}, Hans-Ulrich Häring^{1,2,3}, Hubert Preißl^{1,2}, Andreas L. Birkenfeld^{1,2,3},
8 Andreas Peter^{1,2,5}, Andreas Fritsche^{1,2,3}, Robert Wagner^{1,2,3}

9
10 1. Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center
11 Munich at the University of Tübingen, Tübingen, Germany

12 2. German Center for Diabetes Research (DZD), Neuherberg, Germany

13 3. Department of Internal Medicine, Division of Endocrinology, Diabetology and
14 Nephrology, Eberhard Karls University Tübingen, Tübingen, Germany

15 4. Institute for Clinical Chemistry and Pathobiochemistry, Department for Diagnostic
16 Laboratory Medicine, University Hospital Tübingen, Tübingen, Germany.

17 5. German Institute of Human Nutrition, Potsdam-Rehbrücke, Germany

18

19

20 Corresponding author

21

22 Louise Fritsche, PhD

23 University Hospital Tübingen, Department of Internal Medicine IV

24 Otfried-Müller-Str. 10

25 72076 Tübingen

26 Germany

27 E-mail: louise.fritsche@med.uni-tuebingen.de

28 Phone: +49 7071 2980687

29

30 Word count: 1482

31 Number of figures: 1

32 Number of tables: 2

33 Number of supplementary figures: 3

34

35

36

37

38

39

40

41

42

43

44

45

46 **Abbreviations**

47	AUC	Area under the curve
48	DPP-4	Dipeptidyl Peptidase IV
49	GDM	Gestational diabetes mellitus
50	GIP	Glucose dependent insulinotropic peptide
51	GLP-1	Glucagon like peptide-1
52	GLP-1R	Glucagon like peptide-1 receptor
53	IGI	Insulinogenic index
54	NEFA-ISI	Nonesterified fatty acids - Insulin sensitivity index
55	NGT	Normal glucose tolerance
56	OGTT	Oral glucose tolerance test

57 Abstract

58

59 Background

60 Incretins are crucial stimulators of insulin secretion after food intake. We investigated
61 the incretin response during an oral glucose tolerance test in pregnant women with
62 and without gestational diabetes.

63 Methods

64 Subjects underwent a 5-point OGTT with 75 g glucose. We assessed insulin
65 secretion and levels of total GLP-1, GIP, glicentin and glucagon during the OGTT.

66 Findings

67 We examined 167 women (33 with GDM) during gestational week 26.95 ± 2.15 .
68 Insulin secretion was significantly lower in women with GDM ($p < 0.001$). Postprandial
69 GLP-1 and GIP were ~20% higher in women with GDM (all $p < 0.05$) independent
70 from age, BMI and gestational age. GLP-1 increase associated with insulin secretion
71 only in GDM, but not in NGT. Postprandial GLP-1 levels associated negatively with
72 birth weight.

73 Interpretation

74 The more pronounced GLP-1 increase in women with GDM could be part of a
75 compensatory mechanism counteracting GLP-1 resistance. Higher GLP-1 levels
76 might be protective against fetal overgrowth.

77 Funding

78 This study was supported in part by a grant from the Federal Ministry of Education
79 and Research (BMBF) (01GI0925) to the German Center for Diabetes Research
80 (DZD).

81 **Keywords**

82 GDM, Incretins, GLP-1, birth weight

83 Introduction

84

85 Gestational diabetes mellitus (GDM) affects 13% of pregnancies with increasing
86 incidence. In pregnancy, insulin resistance develops during the 2nd trimester and is
87 normally compensated by an increase in insulin secretion ¹. However, if this
88 compensatory increase in insulin secretion falls short, glucose levels rise and GDM
89 develops. When insulin resistance is resolved after delivery, glucose rapidly
90 normalizes. Nevertheless, women who had GDM are at risk to subsequently develop
91 type 2 diabetes ².

92 After food intake, specialized cells in the gastrointestinal tract release incretin
93 hormones. The best studied incretins are glucagon like peptide 1 (GLP-1) and
94 glucose-dependent insulintropic peptide (GIP). GLP-1 is cleaved from its precursor
95 proglucagon along with other peptides, including glicentin and oxyntomodulin.
96 Proglucagon gene products in pancreatic α -cells give rise to glucagon.

97 GLP-1 and GIP are strong enhancers of glucose-stimulated insulin secretion. This
98 incretin effect is reduced in type 2 diabetes and GDM ³.

99 However, only a few studies investigated GLP-1 and GIP concentrations in GDM and
100 reported contrasting results ⁴⁻⁷. One study investigated glucagon and detected higher
101 fasting and post-glucose-challenge concentrations in GDM ⁸. No studies on glicentin
102 in pregnancy have been published so far.

103 Objective

104 The aim of our study was to investigate the response of incretins and glucagon
105 during an oral glucose tolerance test in pregnancy in a large cohort of well
106 phenotyped women with normal glucose tolerance and GDM using precise pre-
107 analytics and specific immunoassays.

108 Methods

109

110 Subjects

111 We analyzed data from an ongoing study aiming to characterize metabolic alterations
112 during pregnancy (PREG), a cohort study recruiting women undergoing oral glucose
113 tolerance tests for screening of GDM (NCT04270578). Pregnant women were
114 examined between gestational week 24+0 and 31+6 with a 2h-OGTT with 75 g
115 glucose. GDM was diagnosed using the IADPSG criteria ⁹ and patients were
116 subsequently treated according to national guidelines, which was not part of the
117 study. The detailed study protocol has been described elsewhere ¹⁰. Informed written
118 consent was obtained from every study participant. The study protocol has been
119 approved by the local ethics boards and the study is conducted in accordance with
120 the declaration of Helsinki. Patients were not involved in the design of the study.
121 Meetings to connect study participants and researchers are held annually.

122

123 OGTT, laboratory analyses and anthropometric assessment

124 After an overnight fasting period of 12h, all study participants underwent 5-point
125 OGTT with 75 g of glucose. Venous blood was collected at fasting and after 30, 60,
126 90 and 120 minutes. Plasma glucose and nonesterified fatty acids were measured
127 from sodium-fluoride plasma in an ADVIA chemistry XPT autoanalyzer (Siemens
128 Healthcare Diagnostics) at all timepoints. Serum insulin and C-peptide were analyzed
129 using ADVIA Centaur XPT immunoassay system (Siemens AG) at all timepoints. For
130 the measurement of total GIP, total GLP-1, glicentin and glucagon EDTA-plasma
131 from timepoint 0, 30 and 120 minutes was stabilized with 300 ng/mL of the protease
132 inhibitor aprotinin (Sigma, Merck, Germany) und subsequently processed at 4°C and

133 kept frozen at -80°C until batch measurement. Incretins and glucagon were
134 measured with commercially available ELISA assays (Merckodia, Sweden) according
135 to the manufacturer's instructions. Height and weight were measured at the day of
136 OGTT. Pregestational weight, parity, gestational age at birth and birthweight were
137 obtained from maternal medical logs. Birth outcome data were available from 135
138 participants. Insulin sensitivity was calculated using the NEFA-ISI index ¹¹. Insulin
139 secretion was assessed with $\frac{AUC_{C-peptide\ 0-30}}{AUC_{Glucose\ 0-30}}$ and with $\Delta C-peptide_{0-30}$.

140

141 [Statistical analysis](#)

142 All statistical analyses were performed with R Version 3.6.1. In linear regression
143 models skewed variables were log-transformed to approximate normal distribution.
144 Group differences were tested with t-tests for normal distributed variables, Kruskal-
145 Wallis-test for non-normal distributed variables and Chi²-test for categorical variables.
146 The provided β coefficients are standardized estimates of the linear regression model
147 terms. A p-value <0.05 was considered statistically significant.

148

149 [Results](#)

150 We analyzed data from 167 women, in 33 GDM was diagnosed. Patients with GDM
151 were older, more likely to be multiparous, but BMI was not different from women with
152 normal glucose tolerance (NGT; Table 1).

153

154 [Glucose and hormones during OGTT](#)

155 Insulin secretion and sensitivity were lower in GDM (Figure 1 A, B). Areas under the
156 curve (AUCs) of glucose and C-peptide were higher in GDM (Figure 1 C, D). While

157 fasting levels of GLP-1 and GIP were similar, the levels at 30min were higher in GDM
158 (Table 2). The AUCs of GLP-1 and GIP were also higher in GDM (all $p < 0.05$, Figure
159 1 E, F, Table 2). Fasting glicentin, glucagon, and their post-load kinetics were not
160 different between groups ($p \geq 0.1$, Figure 1 G, H, Table 2).

161

162 [GLP-1 associates with insulin secretion only in women with GDM](#)

163 We hypothesized that higher incretin levels in GDM represent a compensatory effect
164 to boost insulin secretion. Therefore, we analyzed the associations of GLP-1 and
165 glucose with insulin secretion (Figure S1). In NGT, increase in glucose between 0-
166 30min associated with insulin secretion (Figure S1 A, $p < 0.0001$). No such association
167 was present for GLP-1 (panel B, $p = 0.43$).

168 In contrast, women with GDM showed no association of glucose (Figure S1 C, $p = 0.6$)
169 but a positive association of GLP-1 with insulin secretion (panel D, $p = 0.0004$). This
170 remained significant after adjustment for glucose change and basal insulin. Glicentin
171 was similarly associated with insulin secretion in GDM and NGT (Figure S2). For GIP
172 there was no association with insulin secretion (Figure S3).

173

174 [Higher GLP-1 associates with lower birth weight](#)

175 Birth weight negatively associated with AUC GLP-1 ($p = 0.0182$, $\beta = -76.94$), 30min
176 GLP-1 ($p = 0.0248$, $\beta = -72.6$) and trend for negative association with 30min GIP
177 ($p = 0.0814$, $\beta = -57.45$, all models adjusted for gestational age at birth, fetal sex and
178 pregestational BMI). Since GLP-1 and GIP concentrations were higher in GDM, the
179 models were additionally adjusted for GDM. Associations of birth weight with AUC
180 GLP-1 and 30min GLP-1 remained significant ($p = 0.0296$, $\beta = -72.43$ and $p = 0.0381$,
181 $\beta = -68.49$, respectively).

182

183 Discussion

184 Main findings

185 In this study, we find significantly higher postprandial GLP-1 and GIP levels in
186 pregnant women with gestational diabetes compared to women with normal glucose
187 tolerance, independent from age, body mass index and gestational age. The
188 postprandial GLP-1 increase associated with insulin secretion in women with GDM
189 but not in women with NGT, where insulin secretion was glucose driven. Offspring of
190 women with higher GLP-1 levels also had lower birth weights.

191 Interpretation

192 GLP-1 and GIP have previously been investigated in women with and without GDM
193 in smaller studies with different results ^{4,6,7,12}. One study used a different stimulus
194 (mixed meal test) ⁶ and large BMI differences ^{6,12} between NGT and GDM subjects
195 might further confound analyses, because BMI negatively associates with GLP-1 and
196 GIP ¹³. Similar BMI between groups allowed analyzing impact of GDM on incretin
197 responses, without adiposity as confounder.

198 Intestinal L-cells also secrete glicentin, a potential biomarker of L-cell secretion ¹⁴.
199 Lack of difference in glicentin between NGT and GDM argues against an unselective
200 L-cell hypersecretion in GDM.

201 In contrast to findings on glucagon outside of pregnancy ¹⁵, we and others ⁶ did not
202 detect links to diabetes. This argues against a major contribution of glucagon in the
203 pathogenesis of GDM, while it might have some value in the prognosis of subsequent
204 insulin requirement for the treatment of GDM ¹⁶.

205 Of note, women with GDM had lower insulin secretion despite higher GLP-1
206 concentrations. Our correlational analyses indicate an important contribution of GLP-
207 1 to insulin secretion, especially in GDM. However, this GLP-1 stimulus is still not

208 sufficient to control hyperglycemia. The failure of adequate insulin secretion despite
209 elevated GLP-1 indicates incretin resistance in GDM. The more pronounced GLP-1
210 response in GDM could be counteracting incretin resistance.

211 One potential contributor to incretin resistance is genetic background.
212 Polymorphisms in *TCF7L2* associate with elevated GDM risk¹⁷ and reduced GLP-1-
213 stimulated insulin secretion¹⁸. Another possible contributor might be dipeptidyl
214 peptidase IV (DPP-4) activity, the enzyme degrading GLP-1 and GIP. Liu et al.¹⁹
215 reported no differences of DPP-4 in maternal serum and the unaltered fasting GLP-1
216 levels in GDM in our study argue against largely different DPP-4 activity.
217 Furthermore, insulin resistance and hyperglycemia which are present in GDM are
218 associated with incretin resistance¹⁸.

219 In our study neonates of women with higher GLP-1 levels during pregnancy had
220 lower birth weight, independent of glycemia. This points towards a protection of GLP-
221 1 against excessive fetal growth. Our findings are in line with a report of negative
222 association between fasting maternal GLP-1 and fetal abdominal circumference and
223 birth weight²⁰. Higher GLP-1, also via decelerated gastric emptying, might reduce
224 postprandial glucose which is associated with fetal overgrowth. If this hypothesis
225 holds true, GLP-1 receptor agonists or DPP-4 inhibitors might have benefits in GDM.
226 To our knowledge, currently no studies test GLP-1R agonists in GDM. One trial
227 reported higher insulin secretion after 16 weeks treatment with the DPP-4 inhibitor
228 sitagliptin in GDM²¹. However, neither incretins nor birth outcomes were reported.

229 **Strengths and limitations**

230 The strength of our study is the large number of subjects of our extensively
231 phenotyped cohort of pregnant women. The sample preparation and measurement of
232 incretins was done according to standard operating procedures and with state-of-the-

233 art measuring method. One weakness is the relatively low number of patients with
234 GDM.

235

236 Conclusion

237 In summary, elevated GLP-1 could be part of a compensatory attempt to counteract
238 GLP-1 resistance in GDM. Higher GLP-1 levels might protect against fetal
239 overgrowth. Our data suggest that not only glucose-stimulated but also incretin-
240 stimulated insulin secretion contributes to GDM. Further studies are needed to
241 translate these findings into improved therapeutic strategies to prevent or treat GDM
242 and circumvent unfavorable impact on the developing child.

243 Acknowledgement

244 We thank all of the volunteers for their participation in the study. We especially thank
245 Ines Wagener, Eva-Maria Stehle, Alexandra Eberle, Dorothee Neuscheler, Henrike
246 Peuker, Elisabeth Metzinger and Heike Runge for their excellent technical
247 assistance.

248

249 Disclosure of interests

250 RW reports lecture fees from NovoNordisk and travel grants from Eli Lilly. He served
251 on the advisory board of Akcea Therapeutics. In addition to his current work, ALB
252 reports lecture fees from Astra Zeneca, Boehringer Ingelheim, and NovoNordisk. He
253 served on advisory boards of Astra Zeneca, Boehringer Ingelheim and NovoNordisk.
254 Besides his current work, AF reports lecture fees and advisory board membership
255 from Sanofi, Novo Nordisk, Eli Lilly, and AstraZeneca. In addition to is current work,

256 MH reports research grants from Boehringer Ingelheim and Sanofi (both to the
257 University Hospital of Tuebingen) and lecture fees from Sanofi, Novo Nordisk, Eli Lilly
258 and Merck Sharp Dohme. None of the other authors report a conflict of interest
259 directly related to the content of this work.
260

261 Contribution of authorship

262 LF researched and analyzed data and drafted the manuscript. JH, SN, and RW
263 researched data. HUH, ALB, HP, AS, and AF contributed to the discussion and
264 interpretation of the results. AP supervised the laboratory measurements and
265 interpreted results. RW and MH supervised the project. All authors contributed to
266 discussion and approved the final manuscript prior to submission. RW is the
267 guarantor of this work and, as such, had full access to all the data in the study and
268 takes responsibility for the integrity of the data and the accuracy of the data analysis.
269

270 Details of Ethics Approval

271 The study protocol has been approved by the ethics board of the University of
272 Tuebingen (No. 218/2012BO2, 06/15/2012).
273

274 Funding

275 This study was supported in part by a grant from the Federal Ministry of Education
276 and Research (BMBF) (01GI0925) to the German Center for Diabetes Research
277 (DZD).
278

279 Registration

280 The PREG Study is registered with clinicaltrials.gov NCT 04270578.

281

282 Data availability

283 All requests for data and materials will be promptly reviewed by the Data Access
284 Steering Committee to verify whether the request is subject to any intellectual
285 property or confidentiality obligations. Individual-level data may be subject to
286 confidentiality. Any data and materials that can be shared will be released via a
287 Material Transfer Agreement.

288

289

290 References

291

292 1. Powe CE, Huston Presley LP, Locascio JJ, Catalano PM. Augmented insulin
293 secretory response in early pregnancy. *Diabetologia*. 2019 Aug 1;62(8):1445–
294 52.

295 2. Kim C, Newton KM, Knopp RH. Gestational Diabetes and the Incidence of Type
296 2 Diabetes. *Diabetes Care*. 2002 Oct 1;25(10):1862–8.

297 3. Kosinski M, Knop FK, Vedtofte L, Grycewicz J, Swierzewska P, Cypryk K, et al.
298 Postpartum reversibility of impaired incretin effect in gestational diabetes
299 mellitus. *Regulatory Peptides*. 2013 Sep 10;186:104–7.

- 300 4. Cypryk K, Vilsbøll T, Nadel I, Smyczyńska J, Holst JJ, Lewiński A. Normal
301 secretion of the incretin hormones glucose-dependent insulinotropic polypeptide
302 and glucagon-like peptide-1 during gestational diabetes mellitus. *Gynecological*
303 *Endocrinology*. 2007 Jan 1;23(1):58–62.
- 304 5. Mosavat M, Omar SZ, Jamalpour S, Tan PC. Serum Glucose-Dependent
305 Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) in
306 association with the Risk of Gestational Diabetes: A Prospective Case-Control
307 Study. Adamska-Patruno E, editor. *Journal of Diabetes Research*. 2020 Jan
308 29;2020:9072492.
- 309 6. Bonde L, Vilsbøll T, Nielsen T, Bagger JI, Svare JA, Holst JJ, et al. Reduced
310 postprandial GLP-1 responses in women with gestational diabetes mellitus.
311 *Diabetes, Obesity and Metabolism*. 2013;15(8):713–20.
- 312 7. Lencioni C, Resi V, Romero F, Lupi R, Volpe L, Bertolotto A, et al. Glucagon-like
313 peptide-1 secretion in women with gestational diabetes mellitus during and after
314 pregnancy. *J Endocrinol Invest*. 2011 Oct;34(9):e287-290.
- 315 8. Beis C, Grigorakis SI, Philippou G, Alevizaki M, Anastasiou E. Lack of
316 suppression of plasma glucagon levels in late pregnancy persists postpartum
317 only in women with previous gestational diabetes mellitus. *Acta Diabetol*. 2005
318 Mar;42(1):31–5.
- 319 9. International Association of Diabetes and Pregnancy Study Groups Consensus
320 Panel, Metzger BE, Gabbe SG, Persson B, Buchanan TA, Catalano PA, et al.
321 International association of diabetes and pregnancy study groups

- 322 recommendations on the diagnosis and classification of hyperglycemia in
323 pregnancy. *Diabetes Care*. 2010 Mar;33(3):676–82.
- 324 10. Fritsche L, Hummel J, Wagner R, Loeffler D, Hartkopf J, Machann J, et al. The
325 German Gestational Diabetes Study (PREG): Rationale, Methodology and
326 Design [Internet]. 2021 [cited 2021 Oct 12]. p. 2021.10.10.21264499. Available
327 from: <https://www.medrxiv.org/content/10.1101/2021.10.10.21264499v1>
- 328 11. Wagner R, Fritsche L, Heni M, Fehlert E, Stefan N, Staiger H, et al. A novel
329 insulin sensitivity index particularly suitable to measure insulin sensitivity during
330 gestation. *Acta Diabetol*. 2016 Dec;53(6):1037–44.
- 331 12. Sukumar N, Bagias C, Goljan I, Weldeselassie Y, Gharanei S, Tan BK, et al.
332 Reduced GLP-1 Secretion at 30 Minutes After a 75-g Oral Glucose Load Is
333 Observed in Gestational Diabetes Mellitus: A Prospective Cohort Study.
334 *Diabetes*. 2018 Dec 1;67(12):2650–6.
- 335 13. Færch K, Torekov SS, Vistisen D, Johansen NB, Witte DR, Jonsson A, et al.
336 GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-Detected
337 Type 2 Diabetes, and Obesity and Influenced by Sex: The ADDITION-PRO
338 Study. *Diabetes*. 2015 Jul;64(7):2513–25.
- 339 14. Perakakis N, Mantzoros CS. The Role of Glicentin and Oxyntomodulin in Human
340 Metabolism: New Evidence and New Directions. *J Clin Endocrinol Metab*. 2020
341 Aug 1;105(8):e3003–5.
- 342 15. Wagner R, Hakaste LH, Ahlqvist E, Heni M, Machann J, Schick F, et al.
343 Nonsuppressed Glucagon After Glucose Challenge as a Potential Predictor for
344 Glucose Tolerance. *Diabetes*. 2017 May 1;66(5):1373–9.

- 345 16. Horie I, Haraguchi A, Ito A, Nozaki A, Natsuda S, Akazawa S, et al. Impaired
346 early-phase suppression of glucagon secretion after glucose load is associated
347 with insulin requirement during pregnancy in gestational diabetes. *J Diabetes*
348 *Investig.* 2020 Jan;11(1):232–40.
- 349 17. Fritsche L, Sarief M, Wagner R, Stefan N, Lehmann R, Häring H-U, et al.
350 Genetic variation in TCF7L2 rs7903146 and history of GDM negatively and
351 independently impact on diabetes-associated metabolic traits. *Diabetes Res Clin*
352 *Pract.* 2018 Dec;146:251–7.
- 353 18. Herzberg-Schäfer S, Heni M, Stefan N, Häring H-U, Fritsche A. Impairment of
354 GLP1-induced insulin secretion: role of genetic background, insulin resistance
355 and hyperglycaemia. *Diabetes, Obesity and Metabolism.* 2012;14(s3):85–90.
- 356 19. Liu B, Deng S, Xu Y, Yang J, Geng H, Wang Z. Association between maternal
357 and umbilical cord serum dipeptidyl peptidase IV in pregnant women with and
358 without gestational diabetes mellitus. *Journal of Obstetrics and Gynaecology*
359 *Research.* 2016;42(5):505–10.
- 360 20. Valsamakis G, Margeli A, Vitoratos N, Boutsiadis A, Sakkas EG, Papadimitriou
361 G, et al. The role of maternal gut hormones in normal pregnancy: fasting plasma
362 active glucagon-like peptide 1 level is a negative predictor of fetal abdomen
363 circumference and maternal weight change. *European Journal of Endocrinology.*
364 2010 May 1;162(5):897–903.
- 365 21. Sun X, Zhang Z, Ning H, Sun H, Ji X. Sitagliptin down-regulates retinol-binding
366 protein 4 and reduces insulin resistance in gestational diabetes mellitus: a
367 randomized and double-blind trial. *Metab Brain Dis.* 2017 Jun 1;32(3):773–8.

368

369

370 Figure legend

371

372 **Figure 1** Insulin secretion (A) and insulin sensitivity (B) in women with and without GDM and time course of
373 glucose (C), C-peptide (D), GLP-1 (E), GIP (F), glicentin (G) and glucagon (H) during OGTT. Data are
374 presented as mean \pm standard error. Blue represent NGT, red GDM. Group differences between GDM and NGT
375 for AUCs of glucose, insulin and C-peptide were tested with Kruskal-Wallis-test. Differences between groups
376 for insulin sensitivity, incretins and glucagon were tested with multivariate linear regression adjusted for age,
377 BMI and gestational week and for insulin secretion additionally adjusted for insulin sensitivity.

378

379 **Tables**

380 **Table 1 Subject characteristics of the pregnant cohort and birth outcome parameters**

Characteristics	NGT (n = 134)	GDM (n = 33)	p	p adjusted
Age	32.71 (4.31)	35.03 (3.84)	0.005*	-
BMI (kg/m²)	26.90 [23.97, 29.94]	26.90 [24.72, 30.99]	0.497	-
Pregestational BMI (kg/m²)	25.37 (5.25)	25.50 (4.96)	0.906	-
Gestational weight gain (kg)	14.06 (5.53)	11.46 (7.10)	0.085	-
Parity (%) Nulliparous Multiparous	69 (51.5) 65 (48.5)	9 (27.37) 24 (72.7)	0.021*	-
Gestational age at OGTT (weeks)	26.87 (2.16)	27.27 (2.11)	0.332	-
Fasting glucose (mmol/L)	4.28 [4.07, 4.54]	4.56 [4.33, 4.94]	<0.001*	-
1 h glucose (mmol/L)	7.70 [6.40, 8.56]	10.61 [9.56, 11.33]	<0.001*	-
2 h glucose (mmol/L)	6.11 [5.34, 6.83]	8.83 [7.72, 9.44]	<0.001*	-
Fasting insulin (pmol/L)	59 [42, 79]	69[41, 84]	0.460	-
Fasting C-peptide (pmol/L)	381.50 [296.50, 496.50]	466.00 [282.00, 652.00]	0.150	-
Insulin sensitivity (NEFA-ISI)	3.34 [2.56, 4.39]	2.72 [2.01, 4.26]	0.031*	0.003*†
Insulin secretion (AUC_{C-pep 0-30}/AUC_{Glucose0-30})	179.22 (60.12)	155.17 (54.53)	0.037*	<0.001*‡
Birth weight (g) #	3478.18 (479.84)	3321.52 (384.38)	0.084	0.24 §
Birth length (cm) #	51.48 (2.37)	50.48 (2.68)	0.042	0.27 §
Gestational age at birth (weeks)⁴	39.51 (1.59)	39.16 (1.17)	0.240	-

381 Data are presented as means (SD), median [IQR] and numbers (%). Group
 382 differences were tested with T-test for normal distributed variables, Kruskal-Wallis-
 383 test for nonnormal distributed variables and Chi2-test for categorical variables.
 384 *indicates statistical significance. † Adjusted for age, BMI and gestational age, ‡
 385 adjusted for age, BMI, gestational age and insulin sensitivity, § adjusted for
 386 gestational age and fetal sex, # n=135. NGT = normal glucose tolerance.
 387



388 Table 2 Incretin concentrations during OGTT and AUCs in the pregnant cohort

Incretin	NGT (n = 134)	GDM (n = 33)	p	p adjusted †
GLP-1 min 0 (pmol/L)	4.48 [3.42, 5.53]	4.83 [3.56, 6.18]	0.393	0.6
GLP-1 min 30 (pmol/L)	9.89 [7.10, 12.83]	11.31 [8.65, 14.98]	0.034*	0.03*
GLP-1 min 120 (pmol/L)	5.71 [4.55, 8.27]	6.48 [5.05, 9.30]	0.175	0.3
AUC GLP-1 (min-pmol/L)	911.19 [726.59, 1207.49]	1136.24 [913.21, 1342.74]	0.03*	0.03*
GIP min 0 (pmol/L)	0.81 [0.81, 1.50]	0.81 [0.81, 1.76]	0.312	0.5
GIP min 30 (pmol/L)	20.21 [14.12, 29.69]	24.12 [18.76, 35.77]	0.049*	0.02*
GIP min 120 (pmol/L)	17.48 [11.92, 23.58]	19.20 [14.96, 27.13]	0.191	0.1
AUC GIP (min-pmol/L)	2022.49 [1421.28, 2887.34]	2532.15 [1899.17, 3219.01]	0.045*	0.04*
Glicentin min 0 (pmol/L)	12.37 [8.53, 16.92]	12.59 [9.56, 16.56]	0.989	0.9
Glicentin min 30 (pmol/L)	25.10 [19.26, 34.73]	28.33 [25.16, 35.13]	0.122	0.1
Glicentin min 120 (pmol/L)	20.17 [14.97, 30.45]	21.66 [14.44, 29.84]	0.602	0.3
AUC Glicentin (min-pmol/L)	2715.75 [2092.97, 3529.69]	2912.80 [2426.76, 3574.03]	0.198	0.1
Glucagon min 0 (pmol/L)	1.45 [0.81, 3.42]	1.43 [0.95, 2.96]	0.873	0.6

Glucagon min 30 (pmol/L)	1.35 [0.55, 2.20]	1.15 [0.78, 2.54]	0.550	0.4
Glucagon min 120 (pmol/L)	0.91 [0.44, 1.53]	0.74 [0.46, 1.50]	1.000	0.9
AUC Glucagon (min·pmol/L)	139.11 [74.68, 236.32]	124.74 [89.05, 262.70]	0.659	0.9

389 Data are presented as median [IQR]. Simple group differences were tested with
390 Kruskal-Wallis-test. † adjusted for age, BMI and gestational week. *indicates
391 statistical significance.

Fig.1



■ NGT ■ GDM

